A randomized, controlled trial of oral propranolol in infantile hemangioma.

BACKGROUND Oral propranolol has been used to treat complicated infantile hemangiomas, although data from randomized, controlled trials to inform its use are limited. METHODS We performed a multicenter, randomized, double-blind, adaptive, phase 2-3 trial assessing the efficacy and safety of a pediatric-specific oral propranolol solution in infants 1 to 5 months of age with proliferating infantile hemangioma requiring systemic therapy. Infants were randomly assigned to receive placebo or one of four propranolol regimens (1 or 3 mg of propranolol base per kilogram of body weight per day for 3 or 6 months). A preplanned interim analysis was conducted to identify the regimen to study for the final efficacy analysis. The primary end point was success (complete or nearly complete resolution of the target hemangioma) or failure of trial treatment at week 24, as assessed by independent, centralized, blinded evaluations of standardized photographs. RESULTS Of 460 infants who underwent randomization, 456 received treatment. On the basis of an interim analysis of the first 188 patients who completed 24 weeks of trial treatment, the regimen of 3 mg of propranolol per kilogram per day for 6 months was selected for the final efficacy analysis. The frequency of successful treatment was higher with this regimen than with placebo (60% vs. 4%, P<0.001). A total of 88% of patients who received the selected propranolol regimen showed improvement by week 5, versus 5% of patients who received placebo. A total of 10% of patients in whom treatment with propranolol was successful required systemic retreatment during follow-up. Known adverse events associated with propranolol (hypoglycemia, hypotension, bradycardia, and bronchospasm) occurred infrequently, with no significant difference in frequency between the placebo group and the groups receiving propranolol. CONCLUSIONS This trial showed that propranolol was effective at a dose of 3 mg per kilogram per day for 6 months in the treatment of infantile hemangioma. (Funded by Pierre Fabre Dermatologie; ClinicalTrials.gov number, NCT01056341.).

[1]  V. Catanzarite,et al.  Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies , 2014, The British journal of dermatology.

[2]  S. Prey,et al.  Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol , 2013, The British journal of dermatology.

[3]  N. Moore,et al.  Double‐blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants < 4 months of age , 2013, The British journal of dermatology.

[4]  A. Izadpanah,et al.  Propranolol versus Corticosteroids in the Treatment of Infantile Hemangioma: A Systematic Review and Meta-Analysis , 2013, Plastic and reconstructive surgery.

[5]  K. Holland,et al.  Initiation and Use of Propranolol for Infantile Hemangioma: Report of a Consensus Conference , 2013, Pediatrics.

[6]  A. Penington,et al.  Use of propranolol for treatment of infantile haemangiomas in an outpatient setting , 2012, Journal of paediatrics and child health.

[7]  C. Price,et al.  Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis. , 2011, Archives of dermatology.

[8]  J. Powell,et al.  Propranolol versus Prednisone in the Treatment of Infantile Hemangiomas: A Retrospective Comparative Study , 2011, Pediatric dermatology.

[9]  A. Zvulunov,et al.  Refractive and structural changes in infantile periocular capillary haemangioma treated with propranolol , 2011, Eye.

[10]  O. Wargon,et al.  A Randomized Controlled Trial of Propranolol for Infantile Hemangiomas , 2011, Pediatrics.

[11]  M. Pepper,et al.  Hemangiomas - current therapeutic strategies. , 2011, The International journal of developmental biology.

[12]  S. Heritier,et al.  An adaptive confirmatory trial with interim treatment selection: Practical experiences and unbalanced randomization , 2011, Statistics in medicine.

[13]  P. Froehlich,et al.  Propranolol as first-line treatment of head and neck hemangiomas. , 2011, Archives of otolaryngology--head & neck surgery.

[14]  S. Barbarot,et al.  Propranolol for treatment of ulcerated infantile hemangiomas. , 2011, Journal of the American Academy of Dermatology.

[15]  L. S. Schultze Kool,et al.  Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. , 2011, Journal of the American Academy of Dermatology.

[16]  C. Zeebregts,et al.  Untreated Hemangiomas: Growth Pattern and Residual Lesions , 2011, Plastic and reconstructive surgery.

[17]  C. Bodemer,et al.  Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. , 2010, The Journal of pediatrics.

[18]  Kathryn M. Haider,et al.  Outpatient treatment of periocular infantile hemangiomas with oral propranolol. , 2010, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

[19]  D. Lipsker,et al.  Propranolol for Severe Infantile Hemangiomas: Follow-Up Report , 2009, Pediatrics.

[20]  Anne W. Lucky,et al.  Growth Characteristics of Infantile Hemangiomas: Implications for Management , 2008, Pediatrics.

[21]  F. Boralevi,et al.  Propranolol for severe hemangiomas of infancy. , 2008, The New England journal of medicine.

[22]  I. Frieden,et al.  Infantile Hemangiomas: How Common Are They? A Systematic Review of the Medical Literature , 2008, Pediatric dermatology.

[23]  Christopher Jennison,et al.  Adaptive Seamless Designs: Selection and Prospective Testing of Hypotheses , 2007, Journal of biopharmaceutical statistics.

[24]  I. Frieden,et al.  Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. , 2007, The Journal of pediatrics.

[25]  Martin Posch,et al.  Testing and estimation in flexible group sequential designs with adaptive treatment selection , 2005, Statistics in medicine.

[26]  Mark J. C. Smeulders,et al.  Prevalentie en kenmerken van hemangiomen bij jonge kinderen , 2005 .

[27]  D. Siegel,et al.  Infantile Hemangiomas: Current Knowledge, Future Directions. Proceedings of a Research Workshop on Infantile Hemangiomas , 2005, Pediatric dermatology.

[28]  B. Drolet,et al.  Treatment of hemangiomas of infancy , 2005, Dermatologic therapy.

[29]  A. Picard,et al.  Traitement par vincristine des hémangiomes graves du nourrisson , 2004 .

[30]  R. Jackson.  The Natural History of Strawberry Naevi , 1998, Journal of cutaneous medicine and surgery.

[31]  R. Geronemus,et al.  Guidelines of care for hemangiomas of infancy , 1997 .

[32]  J. Mulliken,et al.  Interferon alfa‐2a therapy for life‐threatening hemangiomas of infancy , 1992, The New England journal of medicine.

[33]  M. Riché,et al.  Management of alarming hemangiomas in infancy: a review of 25 cases. , 1990, Pediatrics.

[34]  R. Simes,et al.  An improved Bonferroni procedure for multiple tests of significance , 1986 .

[35]  M. Edgerton,et al.  Induced Resolution of Cavernous Hemangiomas following Prednisolone Therapy , 1967, Plastic and reconstructive surgery.

[36]  E. A. Graham,et al.  The Natural History of the Strawberry Nevus , 1960 .

[37]  W. Lister.  THE NATURAL HISTORY OF STRAWBERRY NÆVI , 1938 .

[38]  C. Hess,et al.  Propranolol Use in PHACE Syndrome with Cervical and Intracranial Arterial Anomalies: Collective Experience in 32 Infants , 2013, Pediatric dermatology.

[39]  C. M. van der Horst,et al.  [Prevalence and characteristics of haemangiomas in young children]. , 2005, Nederlands tijdschrift voor geneeskunde.

[40]  A. Picard,et al.  [Vincristine treatment for function- and life-threatening infantile hemangioma]. , 2004, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[41]  R. Geronemus,et al.  Guidelines of care for hemangiomas of infancy. American Academy of Dermatology Guidelines/Outcomes Committee. , 1997, Journal of the American Academy of Dermatology.